Sign up to save your podcasts
Or
Share Ghassan Abou-Alfa, MD, MBA - Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ghassan Abou-Alfa, MD, MBA - Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble
Go online to PeerView.com/XKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is an aggressive, complex disease and is a leading cause of cancer-related deaths worldwide. Research endeavors to mitigate HCC mortality have led to rapid advances, especially in the past two years. Today, clinicians specializing in HCC have various treatment options to select for their patients across the spectrum of the disease, and the therapeutic landscape continues to evolve with promising results from ongoing clinical trials investigating novel approaches. This PeerView MasterClass and Tumor Board on-demand educational activity, based on a symposium held adjunct to the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019), features a panel of multidisciplinary HCC experts who review pivotal evidence on available TKI, antiangiogenic, and checkpoint inhibitor therapies and their optimal treatment sequencing strategies, as well as emerging data on novel combinations and innovative modalities for early- to advanced-stage disease. The experts weave the science into real-world case scenarios, helping to translate the data into practical experiences in the HCC clinic. Upon completion of this activity, participants should be better able to: Summarize recent safety and efficacy evidence of available targeted therapies, such as multikinase inhibitors and monoclonal antibodies, for HCC, Evaluate the significance of new data and ongoing clinical trials with checkpoint inhibitors as treatment options for HCC, Review the potential use of systemic treatments in novel multimodal strategies for intermediate HCC, Construct safe and effective treatment plans across multiple lines of therapy for patients with HCC based on multidisciplinary team–based strategies
View all episodes
By PVI, PeerView Institute for Medical Education
2.7
33 ratings
Go online to PeerView.com/XKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is an aggressive, complex disease and is a leading cause of cancer-related deaths worldwide. Research endeavors to mitigate HCC mortality have led to rapid advances, especially in the past two years. Today, clinicians specializing in HCC have various treatment options to select for their patients across the spectrum of the disease, and the therapeutic landscape continues to evolve with promising results from ongoing clinical trials investigating novel approaches. This PeerView MasterClass and Tumor Board on-demand educational activity, based on a symposium held adjunct to the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019), features a panel of multidisciplinary HCC experts who review pivotal evidence on available TKI, antiangiogenic, and checkpoint inhibitor therapies and their optimal treatment sequencing strategies, as well as emerging data on novel combinations and innovative modalities for early- to advanced-stage disease. The experts weave the science into real-world case scenarios, helping to translate the data into practical experiences in the HCC clinic. Upon completion of this activity, participants should be better able to: Summarize recent safety and efficacy evidence of available targeted therapies, such as multikinase inhibitors and monoclonal antibodies, for HCC, Evaluate the significance of new data and ongoing clinical trials with checkpoint inhibitors as treatment options for HCC, Review the potential use of systemic treatments in novel multimodal strategies for intermediate HCC, Construct safe and effective treatment plans across multiple lines of therapy for patients with HCC based on multidisciplinary team–based strategies
More shows like PeerView Gastroenterology CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
27 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners